These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32853627)

  • 1. Inhibition of notch enhances the anti-atherosclerotic effects of LXR agonists while reducing fatty liver development in ApoE-deficient mice.
    Hao Y; Wang X; Zhang F; Wang M; Wang Y; Wang H; Du Y; Wang T; Fu F; Gao Z; Zhang L
    Toxicol Appl Pharmacol; 2020 Nov; 406():115211. PubMed ID: 32853627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
    Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional interplay between liver X receptor and AMP-activated protein kinase α inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy.
    Ma C; Zhang W; Yang X; Liu Y; Liu L; Feng K; Zhang X; Yang S; Sun L; Yu M; Yang J; Li X; Hu W; Miao RQ; Zhu Y; Li L; Han J; Chen Y; Duan Y
    Br J Pharmacol; 2018 May; 175(9):1486-1503. PubMed ID: 29394501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encapsulation of LXR ligand by D-Nap-GFFY hydrogel enhances anti-tumorigenic actions of LXR and removes LXR-induced lipogenesis.
    Feng K; Ma C; Liu Y; Yang X; Yang Z; Chen Y; Xu T; Yang C; Zhang S; Li Q; Wei Z; Zhao D; Zeng P; Han J; Gao J; Chen Y; Duan Y
    Theranostics; 2021; 11(6):2634-2654. PubMed ID: 33456564
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression.
    Guo Y; Yuan W; Yu B; Kuai R; Hu W; Morin EE; Garcia-Barrio MT; Zhang J; Moon JJ; Schwendeman A; Eugene Chen Y
    EBioMedicine; 2018 Feb; 28():225-233. PubMed ID: 29361501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
    Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver X receptor activation attenuates plaque formation and improves vasomotor function of the aortic artery in atherosclerotic ApoE(-/-) mice.
    Chen J; Zhao L; Sun D; Narsinh K; Li C; Zhang Z; Qi S; Wei G; Li W; Guo W; Cao F
    Inflamm Res; 2012 Dec; 61(12):1299-307. PubMed ID: 22833121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms.
    Verschuren L; de Vries-van der Weij J; Zadelaar S; Kleemann R; Kooistra T
    J Lipid Res; 2009 Feb; 50(2):301-11. PubMed ID: 18757914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of macrophages drives LXR-induced regression both in initial and advanced stages of atherosclerotic lesion development.
    van der Stoep M; Li Z; Calpe-Berdiel L; van der Sluis RJ; Saleh P; McKinnon HJ; Smit MJ; Korporaal SJ; Van Berkel TJ; Van Eck M; Hoekstra M
    Biochem Pharmacol; 2013 Dec; 86(11):1594-602. PubMed ID: 24095721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of MEK1/2 inhibitor and LXR ligand synergistically inhibit atherosclerosis in LDLR deficient mice.
    Yang J; Liu L; Yang X; Duan Y; Zeng P; Yang S; Ma C; Li X; Han J; Chen Y
    Biochem Biophys Res Commun; 2020 Feb; 522(2):512-517. PubMed ID: 31784089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/- mice.
    Dai XY; Ou X; Hao XR; Cao DL; Tang YL; Hu YW; Li XX; Tang CK
    J Cardiovasc Pharmacol; 2008 May; 51(5):467-75. PubMed ID: 18437096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
    Srivastava RA
    Atherosclerosis; 2011 Jan; 214(1):86-93. PubMed ID: 21093860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
    Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling.
    Ide T; Shimano H; Yoshikawa T; Yahagi N; Amemiya-Kudo M; Matsuzaka T; Nakakuki M; Yatoh S; Iizuka Y; Tomita S; Ohashi K; Takahashi A; Sone H; Gotoda T; Osuga J; Ishibashi S; Yamada N
    Mol Endocrinol; 2003 Jul; 17(7):1255-67. PubMed ID: 12730332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. n-3 fatty acids ameliorate hepatic steatosis and dysfunction after LXR agonist ingestion in mice.
    Jung UJ; Millman PN; Tall AR; Deckelbaum RJ
    Biochim Biophys Acta; 2011 Sep; 1811(9):491-7. PubMed ID: 21704188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator.
    Miao B; Zondlo S; Gibbs S; Cromley D; Hosagrahara VP; Kirchgessner TG; Billheimer J; Mukherjee R
    J Lipid Res; 2004 Aug; 45(8):1410-7. PubMed ID: 15145986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels.
    van der Hoorn J; Lindén D; Lindahl U; Bekkers M; Voskuilen M; Nilsson R; Oscarsson J; Lindstedt E; Princen H
    Br J Pharmacol; 2011 Apr; 162(7):1553-63. PubMed ID: 21175581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression.
    Ou X; Dai X; Long Z; Tang Y; Cao D; Hao X; Hu Y; Li X; Tang C
    Sci China C Life Sci; 2008 May; 51(5):418-29. PubMed ID: 18785587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia.
    Kratzer A; Buchebner M; Pfeifer T; Becker TM; Uray G; Miyazaki M; Miyazaki-Anzai S; Ebner B; Chandak PG; Kadam RS; Calayir E; Rathke N; Ahammer H; Radovic B; Trauner M; Hoefler G; Kompella UB; Fauler G; Levi M; Levak-Frank S; Kostner GM; Kratky D
    J Lipid Res; 2009 Feb; 50(2):312-26. PubMed ID: 18812595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver X receptor agonist T0901317.
    Peng D; Hiipakka RA; Reardon CA; Getz GS; Liao S
    Atherosclerosis; 2009 Mar; 203(1):59-66. PubMed ID: 18639878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.